Table 2.
Summary of key retrospective series of post-MPN AML
| Study | Year | N | Treatment | CR/CRi, % | mOS in months/OS |
|---|---|---|---|---|---|
| Supportive care regimens | |||||
| Tam et al8 | 2008 | 19 | Transfusion alone ± hydroxyurea | 0 | 1.5/5% (@ 1 y) |
| Venton et al71 | 2018 | 28 | 0 | 1.8 | |
| Mesa et al25 | 2005 | 48 | Transfusion alone ± hydroxyurea | 0 | 2.0 |
| McNamara et al61 | 2018 | 51 | 0 | 2.0/9% (@ 2 y) | |
| Passamonti et al93 | 2005 | 7 | 0 | 2.5 | |
| Low-intensity regimens/HMA therapy | |||||
| Passamonti et al93 | 2005 | 8 | Low-dose chemo: 6-thyoguanine, cytarabine | NR | 2.5 |
| — | HMA: N/A | — | — | ||
| Mesa et al25 | 2005 | 19 | Low-dose chemo: vincristine, melphalan/busulfan, cytarabine | NR | 2.9 |
| — | HMA: N/A | — | — | ||
| Kennedy et al26 | 2013 | 5 | Low-dose chemo: low-dose cytarabine, others | 6.3 | 6.6 |
| 6 | HMA: azacytidine, decitabine | ||||
| Badar et al96 | 2015 | — | Low-dose chemo: N/A | — | — |
| 21 | HMA: decitabine (± ruxolitinib or gemtuzumab) | 14 | 6.9 | ||
| Tam et al8 | 2008 | 8 | Low-dose chemo: gemtuzumab, vincristine + pred, other | 0 | 7.0 |
| 4 | HMA: azacytidine (+ valproic acid + ATRA), decitabine | ||||
| Chihara et al92 | 2016 | 52 | Low-dose chemo: low-dose cytarabine | 36 | 8.0 |
| 99 | HMA: (not defined) | 30 | 7.8 | ||
| Venton et al71 | 2018 | — | Low-dose chemo: N/A | — | — |
| 11 | HMA: azacytidine | NR | 7.9 | ||
| Thepot et al114 | 2010 | — | Low-dose chemo: N/A | — | — |
| 26 | HMA: azacytidine (7 d) | 16 | 8.0 | ||
| Mascarenhas et al87 | 2010 | — | Low-dose chemo: N/A | — | — |
| 6 | HMA: decitabine (5 d) | 50 | >9 | ||
| Andriani et al94 | 2015 | — | Low-dose chemo: N/A | — | — |
| 19 | HMA: azacytidine | 26 | 9.9/37% (@ 1 y) | ||
| Induction chemotherapy regimens | |||||
| Mesa et al25 | 2005 | 24 | Cytarabine ± anthracycline | 0 | 3.9 |
| Passamonti et al93 | 2005 | 8 | Cytarabine ± idarubicin, or fludarabine-based | 13 | 5.6 |
| Tam et al8 | 2008 | 36 | Cytarabine ± anthracycline | 46 | 6.0 |
| Noor et al27 | 2011 | 20 | Cytarabine + anthracycline | 0 | 6.0/30% (@ 1 y) |
| Chihara et al92 | 2016 | 71 | High-dose cytarabine | 39 | 7.1 |
| Venton et al71 | 2018 | 34 | NR | 8.3 | |
| Kennedy et al26 | 2013 | 13 | Cytarabine + anthracycline or NOVE-HIDAC | 47 | 9.4/15% (@ 2 y) |
| Allogeneic stem cell transplant | |||||
| Chihara et al92 | 2016 | 46 | 15.3 | ||
| Tefferi et al18 | 2018 | 24 | 17.5/32% (@ 3 y) | ||
| Mascarenhas et al87 | 2010 | 5 | >18/53% (@ 2 y) | ||
| Cahu et al19 | 2014 | 60 | NR/18% (@ 3 y) | ||
| Alchalby et al89 | 2014 | 46 | NR/33% (@ 3 y) | ||
| Cherington et al88 | 2012 | 8 | >20/75% [PFS] (@ 2 y) | ||
| Ciurea et al91 | 2010 | 14 | 31/49% (@ 2 y) | ||
| Tam et al8 | 2008 | 8 | >31/73% (@ 2 y) | ||
| Kennedy et al26 | 2013 | 17 | 47/47% (@ 2 y) |
—, not applicable; @, at; ATRA, all-trans retinoic acid; chemo, chemotherapy; mOS, median overall survival; N/A, not applicable; NOVE-HIDAC, nilotinib combined with mitoxantrone, etoposide, and high-dose cytarabine; NR, not reported; PFS, progression-free survival; pred, prednisone.